These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

601 related items for PubMed ID: 21325070

  • 1. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.
    Weber J, Atkins M, Hwu P, Radvanyi L, Sznol M, Yee C, Immunotherapy Task Force of the NCI Investigational Drug Steering Committee.
    Clin Cancer Res; 2011 Apr 01; 17(7):1664-73. PubMed ID: 21325070
    [Abstract] [Full Text] [Related]

  • 2. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
    Liu S, Etto T, Rodríguez-Cruz T, Li Y, Wu C, Fulbright OJ, Hwu P, Radvanyi L, Lizée G.
    J Immunother; 2010 May 01; 33(4):371-81. PubMed ID: 20386469
    [Abstract] [Full Text] [Related]

  • 3. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
    Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, Levy D, Kubi A, Hovav E, Chermoshniuk N, Shalmon B, Hardan I, Catane R, Markel G, Apter S, Ben-Nun A, Kuchuk I, Shimoni A, Nagler A, Schachter J.
    Clin Cancer Res; 2010 May 01; 16(9):2646-55. PubMed ID: 20406835
    [Abstract] [Full Text] [Related]

  • 4. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.
    Li Y, Liu S, Hernandez J, Vence L, Hwu P, Radvanyi L.
    J Immunol; 2010 Jan 01; 184(1):452-65. PubMed ID: 19949105
    [Abstract] [Full Text] [Related]

  • 5. Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy.
    Itzhaki O, Hovav E, Ziporen Y, Levy D, Kubi A, Zikich D, Hershkovitz L, Treves AJ, Shalmon B, Zippel D, Markel G, Shapira-Frommer R, Schachter J, Besser MJ.
    J Immunother; 2011 Mar 01; 34(2):212-20. PubMed ID: 21304398
    [Abstract] [Full Text] [Related]

  • 6. Absence of amplification of CD4+CD25(high) regulatory T cells during in vitro expansion of tumor-infiltrating lymphocytes in melanoma patients.
    Knol AC, Lemaître F, Pandolfino MC, Volteau C, Quéreux G, Saiagh S, Khammari A, Viguier M, Dréno B.
    Exp Dermatol; 2008 May 01; 17(5):436-45. PubMed ID: 18312383
    [Abstract] [Full Text] [Related]

  • 7. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes.
    Ogasawara M, Rosenberg SA.
    Cancer Res; 1993 Aug 01; 53(15):3561-8. PubMed ID: 8101762
    [Abstract] [Full Text] [Related]

  • 8. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
    Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Schallmach E, Kubi A, Shalmon B, Hardan I, Catane R, Segal E, Markel G, Apter S, Nun AB, Kuchuk I, Shimoni A, Nagler A, Schachter J.
    J Immunother; 2009 May 01; 32(4):415-23. PubMed ID: 19342963
    [Abstract] [Full Text] [Related]

  • 9. Adoptive T-cell transfer in melanoma.
    Itzhaki O, Levy D, Zikich D, Treves AJ, Markel G, Schachter J, Besser MJ.
    Immunotherapy; 2013 Jan 01; 5(1):79-90. PubMed ID: 23256800
    [Abstract] [Full Text] [Related]

  • 10. The therapeutic efficacy of murine anti-tumor T cells: freshly isolated T cells are more therapeutic than T cells expanded in vitro.
    Evans R, Kamdar SJ, Duffy TM, Krupke DM, Fuller JA, Dudley ME.
    Anticancer Res; 1995 Jan 01; 15(2):441-7. PubMed ID: 7763019
    [Abstract] [Full Text] [Related]

  • 11. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
    Roszkowski JJ, Lyons GE, Kast WM, Yee C, Van Besien K, Nishimura MI.
    Cancer Res; 2005 Feb 15; 65(4):1570-6. PubMed ID: 15735047
    [Abstract] [Full Text] [Related]

  • 12. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
    Maeurer MJ, Martin D, Elder E, Storkus WJ, Lotze MT.
    Clin Cancer Res; 1996 Jan 15; 2(1):87-95. PubMed ID: 9816095
    [Abstract] [Full Text] [Related]

  • 13. Tumor-infiltrating lymphocytes in melanoma.
    Lee S, Margolin K.
    Curr Oncol Rep; 2012 Oct 15; 14(5):468-74. PubMed ID: 22878966
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Flow cytometry assessment of residual melanoma cells in tumor-infiltrating lymphocyte cultures.
    Richards JO, Treisman J, Garlie N, Hanson JP, Oaks MK.
    Cytometry A; 2012 May 15; 81(5):374-81. PubMed ID: 22467596
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma.
    Markel G, Cohen-Sinai T, Besser MJ, Oved K, Itzhaki O, Seidman R, Fridman E, Treves AJ, Keisari Y, Dotan Z, Ramon J, Schachter J.
    Anticancer Res; 2009 Jan 15; 29(1):145-54. PubMed ID: 19331144
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Application of gene therapy in tumor adoptive immunotherapy].
    Wang C, Zhao Y.
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Apr 15; 25(2):482-6. PubMed ID: 18610648
    [Abstract] [Full Text] [Related]

  • 20. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
    Wong JT, Pinto CE, Gifford JD, Kurnick JT, Kradin RL.
    J Immunol; 1989 Nov 15; 143(10):3404-11. PubMed ID: 2509557
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.